JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2002) 175, 297-305       DOI: 10.1677/joe.0.1750297
© 2002 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, S.
Right arrow Articles by Li, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, S.
Right arrow Articles by Li, J.
Journal of Endocrinology, Vol 175, Issue 2, 297-305
Copyright © 2002 by Society for Endocrinology


Articles

Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation

SA Li, SJ Weroha, O Tawfik, and JJ Li


There is increasing evidence that both endogenous and exogenously ingested estrogens play a primary role in sporadic breast cancer causation. To establish further that solely estrogen-induced mammary oncogenesis in female ACI rats is an estrogen receptor (ERalpha)-driven process, we show for the first time that concomitant treatment with the antiestrogen, tamoxifen citrate (TAMc), completely prevents the induction of 17beta-estradiol (E(2))-induced mammary gland tumors (MGTs). This finding is also supported by the reduced mammary gland (MG) lobulo-alveolar development and proliferative activity observed in TAMc+E(2)-treated animals compared with MGs from animals treated with E(2) alone. These data also correlated with a marked decrease in the number of MG cells expressing ERalpha and progesterone receptor (PR) in immunostained MG tissue sections from TAMc+E(2)-treated animals. Additionally, a marked decline in the level of expression of ERalpha 47, 56 and 66 kDa forms, and PR-A and PR-B was seen in TAMc+E(2)-treated MGs, compared with MGs treated solely with E(2). Thus, both ERalpha and PR MG profiles in TAMc+E(2)-treated rats essentially revert to their respective receptor profiles seen in untreated control and TAMc-alone-treated rats. The presence of 56 and 54 kDa isoforms in chronically E(2)-treated MGs and in MGTs respectively may contribute to fostering the enhanced E(2)-dependent growth response of both precursor and frank MGT epithelial cells. These findings are consistent with an ERalpha/PR-mediated mg cell proliferation, a prerequisite for generating the high frequency of chromosomal instability seen in E(2)-induced ductal carcinomas in situ and primary MGTs in female ACI rats reported by us previously.


This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
A. Y. Ting, B. F. Kimler, C. J. Fabian, and B. K. Petroff
Tamoxifen Prevents Premalignant Changes of Breast, but not Ovarian, Cancer in Rats at High Risk for Both Diseases
Cancer Prevention Research, December 1, 2008; 1(7): 546 - 553.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. H. Lee, Y. Zhu, K. M Govindasamy, and G. Gopalan
Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells
Endocr. Relat. Cancer, September 1, 2008; 15(3): 765 - 775.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. G. Kurz, K. K. Hansen, M. T. McLaughlin, V. Shivaswamy, B. S. Schaffer, K. A. Gould, R. D. McComb, J. L. Meza, and J. D. Shull
Tissue-Specific Actions of the Ept1, Ept2, Ept6, and Ept9 Genetic Determinants of Responsiveness to Estrogens in the Female Rat
Endocrinology, August 1, 2008; 149(8): 3850 - 3859.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. W. Blank, P.-Y. Wong, R. Lakshmanaswamy, R. Guzman, and S. Nandi
Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats
PNAS, March 4, 2008; 105(9): 3527 - 3532.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Y. Ting, B. F. Kimler, C. J. Fabian, and B. K. Petroff
Characterization of a preclinical model of simultaneous breast and ovarian cancer progression
Carcinogenesis, January 1, 2007; 28(1): 130 - 135.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Mesia-Vela, R. I. Sanchez, K. R. Reuhl, A. H. Conney, and F. C. Kauffman
Phenobarbital Treatment Inhibits the Formation of Estradiol-Dependent Mammary Tumors in the August-Copenhagen Irish Rat
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 590 - 597.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S.J. Weroha, S. A. Li, O. Tawfik, and J. J. Li
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats
Carcinogenesis, March 1, 2006; 27(3): 491 - 498.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. J. Li, S. J. Weroha, W. L. Lingle, D. Papa, J. L. Salisbury, and S. A. Li
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats
PNAS, December 28, 2004; 101(52): 18123 - 18128.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
V K Turan, R I Sanchez, J J Li, S A Li, K R Reuhl, P E Thomas, A H Conney, M A Gallo, F C Kauffman, and S Mesia-Vela
The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17{beta}-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16{alpha}-hydroxyestradiol, and 4-hydroxyestrone
J. Endocrinol., October 1, 2004; 183(1): 91 - 99.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.